Jill M. Kolesar, professor (CHS) in the Pharmacy Practice Division, has received funding to support two clinical trials on lung cancer research from the Frontier Science & Technology Research Foundation, Inc. (FSTRF)

Based at UW Carbone Cancer Center, the trials will focus on development of a model to predict progression free survival after treatment with Erlotinib.

FSTRF is a not-for-profit research foundation established to advance the application of statistical science and practice and data management techniques in science, health care, and education. The Foundation is currently engaged in large-scale national and international clinical trials related to the treatment of cancer and AIDS patients.